# US 2022/0033378 A1 · Novel n-(isopropyl-triazolyl)pyridinyl)-heteroaryl-carboxamide derivatives and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033378 A1
- Document ID: US20220033378A1
- Status: Published application
- Kind: A1
- Application number: 17/276,490
- Filed: 2019-10-10
- Published: 2022-02-03
- Earliest claimed: 2018-10-18
- Assignees: Hk Inno.N Corporation
- Applicants: Hk Inno.N Corporation
- Inventors: Dongkyu Kim; Seungin Kim; Jaeho Yoo; Seunghee Ji; Joo-hwan Kim; Joonseok Byun; Jinwoo Jung; Soo-jin Kim; Yeji Byeon; Jiwon Choi
- Web page: https://patentgrep.com/patent/US20220033378A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to novel N-(isopropyl-triazolyl)pyridinyl)-heteroaryl-carboxamide derivatives or pharmaceutically acceptable salts thereof; a preparation method thereof; and use for preventing or treating an ASK-1 mediated disease comprising the same as an active ingredient.

## Claims

### Claim 1

A compound represented by Chemical Formula 1 below, or a pharmaceutically acceptable salt thereof:
in the Chemical Formula 1,
X is NH, O or S,
R1 is hydrogen, C1-6 alkyl, C1-6 heteroalkyl, C1-6 alkoxy, or halogen, and
R2 and R3 are each independently hydrogen, C1-6 alkyl, C1-6 heteroalkyl, C1-6 alkoxy, halogen, cyano, nitro, amino, C1-6 alkoxy-C1-6 alkyl, C6-10 aryl, C6-10 arylamino, C5-10 heteroaryl, or C5-10 heteroarylamino,
wherein the aryl or heteroaryl is unsubstituted or substituted with at least one selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, halogen, nitro, cyano, amino, C1-6 alkylamino, acetylamino, formyl, C1-6 alkylcarbonyl, morpholinocarbonyl, morpholinyl, piperazinyl, piperidinyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di(C1-6 alkyl)aminocarbonyl, C1-6 alkyl-thio, cyano-C1-6 alkyl, C1-6 haloalkyl, C1-6 dihaloalkyl, C1-6 alkylsulfonyl, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, C1-6 heteroalkyl, and heteroaryl-C1-6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X is NH, and R1 is hydrogen.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, C6-10 aryl, or C5-10 heteroaryl.

### Claim 4 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are each independently hydrogen, methyl, ethyl, methoxymethyl, or unsubstituted or substituted phenyl, thiophenyl or pyrimidinyl.

### Claim 5 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the aryl or heteroaryl is unsubstituted or substituted with at least one selected from the group consisting of methyl, chloro, fluoro, ethoxy, methylthio, and methylsulfonyl.

### Claim 6 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is
1. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methyl-1H-pyrrole-2-carboxamide,
2. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-m-tolyl-1H-pyrrole-2-carboxamide,
3. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-(methoxymethyl)-1H-pyrrole-2-carboxamide,
4. 4-ethyl-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
5. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-p-tolyl-1H-pyrrole-2-carboxamide,
6. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-phenyl-1H-pyrrole-2-carboxamide,
7. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
8. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-methyl-1H-pyrrole-2-carboxamide,
9. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-phenyl-1H-pyrrole-2-carboxamide,
10. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-p-tolyl-1H-pyrrole-2-carboxamide,
11. 5-ethyl-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
12. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-(2-methylpyrimidine-5-yl)-1H-pyrrole-2-carboxamide,
13. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-(4-(methylsulfonyl)phenyl)-1H-pyrrole-2-carboxamide,
14. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-m-tolyl-1H-pyrrole-2-carboxamide,
15. 5-(3,5-dimethylphenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
16. 5-(4-chlorophenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
17. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-(thiophene-2-yl)-1H-pyrrole-2-carboxamide,
18. 5-(3,4-dimethylphenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
19. 5-(3-fluoro-4-methylphenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
20. 5-(3-chloro-4-fluorophenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide,
21. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-(4-(methylthio)phenyl)-1H-pyrrole-2-carboxamide,
22. N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-o-tolyl-1H-pyrrole-2-carboxamide,
23. 5-(4-fluorophenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide, or
24. 5-(4-ethoxyphenyl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-1H-pyrrole-2-carboxamide.

### Claim 7 (depends on 1)

A method for preparing the compound according to claim 1, comprising:
reacting a compound represented by Chemical Formula 2 below with 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine:
in the Chemical Formula 2,
X is NH, O or S,
Y is OH or halogen, and
R1 to R3 are as defined in claim 1 above.

### Claim 8 (depends on 7)

The method of claim 7, wherein, if Y is OH, the reaction is performed in the presence of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) and a base.

### Claim 9 (depends on 7)

The method of claim 7, wherein, if Y is halogen, the reaction is performed in the presence of triethylamine.

### Claim 10 (depends on 9)

The method of claim 9, wherein the compound of Chemical Formula 2, wherein Y is halogen, is prepared by a reaction of the compound of Chemical Formula 2, wherein Y is OH, with oxalyl halide.

### Claim 11 (depends on 1)

A pharmaceutical composition for preventing or treating an ASK-1 mediated disease, comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, which inhibits ASK-1 activity.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the ASK-1 mediated disease is selected from the group consisting of diabetes, diabetic nephropathy, kidney disease, kidney fibrosis, lung fibrosis, idiopathic pulmonary fibrosis (IPF), liver fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), acute lung injury, nonalcoholic steatohepatitis, liver disease, alcoholic liver disease, alcoholic hepatitis, inflammatory condition, autoimmune disease, proliferative disease, transplantation rejection, a disease accompanying impairment of cartilage turnover, congenital cartilage malformation, a disease associated with hypersecretion of IL6, and a combination thereof.

### Claim 14 (depends on 11)

A method for preventing or treating an ASK-1 mediated disease, including administering a therapeutically effective amount of the pharmaceutical composition according to claim 11 to a subject in need thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the administration of the pharmaceutical composition inhibits ASK-1 activity.

### Claim 16 (depends on 14)

The method of claim 14, wherein the ASK-1 mediated disease is selected from the group consisting of diabetes, diabetic nephropathy, kidney disease, kidney fibrosis, lung fibrosis, idiopathic pulmonary fibrosis (IPF), liver fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), acute lung injury, nonalcoholic steatohepatitis, liver disease, alcoholic liver disease, alcoholic hepatitis, inflammatory condition, autoimmune disease, proliferative disease, transplantation rejection, a disease accompanying impairment of cartilage turnover, congenital cartilage malformation, a disease associated with hypersecretion of IL6, and a combination thereof.
